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Abstract
Background
The harm benefit analysis (HBA) is the cornerstone of animal research regulation and is
considered to be a key ethical safeguard for animals. The HBA involves weighing the antici-
pated benefits of animal research against its predicted harms to animals but there are
doubts about how objective and accountable this process is.
Objectives
i. To explore the harms to animals involved in pre-clinical animal studies and to assess
these against the benefits for humans accruing from these studies; ii. To test the feasibility
of conducting this type of retrospective HBA.
Methods
Data on harms were systematically extracted from a sample of pre-clinical animal studies
whose clinical relevance had already been investigated by comparing systematic reviews of
the animal studies with systematic reviews of human studies for the same interventions
(antifibrinolytics for haemorrhage, bisphosphonates for osteoporosis, corticosteroids for
brain injury, Tirilazad for stroke, antenatal corticosteroids for neonatal respiratory distress
and thrombolytics for stroke). Clinical relevance was also explored in terms of current clinical
practice. Harms were categorised for severity using an expert panel. The quality of the
research and its impact were considered. Bateson’s Cube was used to conduct the HBA.
Results
The most common assessment of animal harms by the expert panel was ‘severe’. Reported
use of analgesia was rare and some animals (including most neonates) endured significant
procedures with no, or only light, anaesthesia reported. Some animals suffered iatrogenic
harms. Many were kept alive for long periods post-experimentally but only 1% of studies
reported post-operative care. A third of studies reported that some animals died prior to end-
points. All the studies were of poor quality. Having weighed the actual harms to animals
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against the actual clinical benefits accruing from these studies, and taking into account the
quality of the research and its impact, less than 7% of the studies were permissible accord-
ing to Bateson’s Cube: only the moderate bisphosphonate studies appeared to minimise
harms to animals whilst being associated with benefit for humans.
Conclusions
This is the first time the accountability of the HBA has been systematically explored across a
range of pre-clinical animal studies. The regulatory systems in place when these studies
were conducted failed to safeguard animals from severe suffering or to ensure that only ben-
eficial, scientifically rigorous research was conducted. Our findings indicate a pressing need
to: i. review regulations, particularly those that permit animals to suffer severe harms; ii.
reform the processes of prospectively assessing pre-clinical animal studies to make them fit
for purpose; and iii. systematically evaluate the benefits of pre-clinical animal research to
permit a more realistic assessment of its likely future benefits.
Introduction
Many countries require research projects using animals to be independently evaluated by a
competent authority as part of the approval or licensing process. This prospective evaluation
often involves weighing the anticipated benefits of the research against its predicted harms to
animals. In the European Union (EU) a harm benefit analysis (HBA) is conducted to assess
‘whether the harm to the animals in terms of suffering, pain and distress is justified by the
expected outcome’ and whether the research ‘may ultimately benefit human beings, animals or
the environment.’[1] (Article 38) The HBA has been a legal requirement in the UK since the
Animals (Scientific Procedures) Act 1986. Since then several other countries including Nor-
way, Brazil, Tanzania and Australia have adopted similar provisions.[2] Scientists using ani-
mals for research in European Union (EU) member states have been required to conduct a
HBA since 2013.[1] Whilst the United States Department of Agriculture Animal Welfare Act
does not require a HBA to be performed, the US Institutional Animal Care and use Committee
is obliged to weigh the objectives of each study against its potential harms to animals.[2] Else-
where there appears to be no formal requirement for a HBA, with animal research being con-
ducted according to guiding principles (e.g. Japan), local laws, or subject to approval by ethics
committees (e.g. Canada).
There are growing doubts about whether the HBA process is sufficiently consistent and
objective, with increasing calls for it to become more transparent, systematic and accountable.
[2–11] The UK government’s Animals in Science Committee (ASC), has recently recom-
mended that methods for prospectively assessing harms and benefits should be continually
improved and updated and that societal concerns about animal research should be explored
and addressed.[12] Public support for animal research is conditional upon the minimisation
of harms to animals and upon benefits to humans and other animals;[11] however in the UK
at least, only 41% of the public trusts scientists not to cause unnecessary suffering to animals.
[13] At present public scrutiny of the HBA process is not possible because although non-tech-
nical project summaries of approved license applications are publicly available in the UK[14]
and other EU countries, they do not include the severity category of the research and cannot
be linked to publications reporting the outcome of that research (due to anonymity). Directive
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2010/63/EU (Article 39: 2) requires researchers using non-human primates and /or severe pro-
cedures to conduct retrospective assessments of their individual projects[15] but it is unclear
whether these will be made publicly available.
Accountability however, can be explored by investigating the outcomes of earlier decisions
to approve animal studies, i.e. by finding out what benefits have actually accrued from animal
studies that have already been conducted and what these studies actually involved in terms of
harms to animals. This type of retrospective HBA might also improve the process of conduct-
ing prospective HBAs, by suggesting criteria for assessing benefits or by providing a more real-
istic view of the likely benefit of animal studies based on past experience. Whilst potential
benefits might include increased knowledge or safety, our interest here is in the clinical benefit
of animal research for humans. However there are challenges involved in this type of retro-
spective HBA, particularly with regard to determining clinical benefit. The ideal is to use sys-
tematic review data (rather than data from single studies) but while systematic reviews of pre-
clinical animal studies investigate treatment effects in animals (and scientific rigour) they do
not tend to consider relevance for humans. Thus the immediate obstacle to conducting a retro-
spective HBA of pre-clinical animal research is the lack of systematic data available on clinical
benefit.
There have been various attempts to evaluate the clinical benefits of animal research for
humans, including consulting physicians for their views[16], historical investigation of drug
developments,[17, 18] citation analysis to track the flow of knowledge from the laboratory to
the clinic,[19] tracking studies that clearly indicate future clinical application,[20] assessing
research ‘payback’[21] and comparing findings from systematic reviews of animal studies with
systematic reviews of humans studies for the same interventions. [22] After considering the
available options we decided that the latter study, published in 2007 by Perel et al,[22] provided
the most suitable data for a retrospective HBA, not only because the study was rigorous and
considered a range of treatment interventions but also because the studies reviewed had been
conducted sufficiently long ago for their clinical benefits to be assessed.
Our aims were to reanalyse Perel et al’s data to i. explore the actual harms to animals
involved in the studies and to assess these against the actual benefits for humans accruing from
these studies; and ii. test the feasibility of the retrospective HBA method. To our knowledge
this is the first time this type of systematic retrospective HBA has been attempted.
Methods
Perel et al’s sample
Perel et al[22] identified 6 interventions for which there was unambiguous systematic review
evidence of a treatment effect for humans: corticosteroids for brain injury, antenatal cortico-
steroids for neonatal respiratory distress, bisphosphonates for osteoporosis, antifibrinolytics
for haemorrhage, thrombolytics for stroke and Tirilazad for stroke. Having identified these
interventions, they searched for all published and unpublished controlled animal studies for
the same 6 interventions, with no restriction by date of publication. To be eligible for inclusion
the studies had to report outcomes corresponding to those for which a treatment effect (either
positive or negative) had been shown in clinical trials. The authors identified and systemati-
cally reviewed 228 animal studies relating to the 6 interventions. They assessed the methodo-
logical quality of the animal studies based on measures taken to prevent bias (allocation
concealment, blinded assessment of outcome and random allocation to groups) as ‘poor’ for
studies in all 6 interventions. Comparing the results from the systematic reviews of animal
studies with the systematic reviews of clinical studies they found that two interventions (bis-
phosphonates, thrombolytics) were concordant, i.e. the findings from the animal studies
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agreed with the findings from the human studies, one intervention was partially concordant
(antenatal corticosteroids) and three were discordant (corticosteroids, Tirilazad and antifibri-
nolytics). Concordance between animal and human studies suggests that the animal studies
represent or model the human condition adequately. Thus concordance provides an indica-
tion of clinical relevance, although it does not necessarily imply that the animal studies led
directly to human benefit. A limitation is that Perel et al do not state how they selected the 6
interventions from among other potentially relevant interventions, but as our purpose is to
test the feasibility of conducting a retrospective HBA (not to obtain a random sample of animal
research), their sample is appropriate, particularly since it contains a range of interventions
and spread in terms of concordance/ discordance. We searched for the 228 animal studies and
noted their citation scores at the time of retrieval (May—June 2015).
Data extraction on harms
Perel et al did not document animal harms, nor welfare and reported animal numbers only
where methodologically relevant. We systematically extracted data on harms, welfare and ani-
mal numbers from each of the studies, with a second reviewer conducting independent data
extraction on a random sample of 20% of papers (n = 42) to check the accuracy and consis-
tency of the process.
We extracted data on the procedures animals underwent, including use of anaesthesia, par-
alytic agents or painkillers, post-operative care, how and when animals were killed, any unex-
pected deaths or events and the species and number of animals used. Every effort was made to
correctly document animal numbers (by carefully scrutinising the text and tables) but due to
poor reporting estimates occasionally had to be made using all available information. We have
indicated where this is the case.
We extracted welfare information where this was available, including any mention of diet,
water and housing (i.e. individual / group housing, paddocks, metabolic cages, temperature,
lighting). Very rarely information was found on animal stress, purchase, quarantine, transport,
handling, breeding, mating and monitoring; this was also extracted. We noted whether studies
reported that they had ethical approval or had followed guidelines.
Expert panel to categorise the severity of harms
A panel of experts from the School of Veterinary Sciences (University of Bristol) was convened
to categorise the severity of harms. The panel consisted of 2 professors, 3 senior research fel-
lows and 1 senior lecturer in animal welfare. Five of the panel members have PhDs in animal
welfare science, 3 are veterinary surgeons (2 holding the RCVS Diploma in Animal Welfare
Science, Ethics and Law) and all are actively engaged in animal welfare research (including
pain perception in rats and sheep, assessment of central pain processing in dogs, development
of automated tests of laboratory animal welfare, and humane slaughter of farm, laboratory and
wild animals).
The EU’s severity classification (Annex VIII) was used since it is employed by the EU regu-
latory bodies when performing HBAs[1] and because it is similar to the American system;
both classify pain, suffering and distress into categories of mild, moderate or severe.[23] The
first author ran the scoring workshop and the second author observed. Rather than asking the
panel to assess all the studies, members were asked to assess typical procedures for each of the
6 interventions (corticosteroids, thrombolytics, etc.), including a range of actual endpoints.
The antifibrinolytic studies were too varied to summarise as they employed markedly different
methods of inducing bleeding and aimed to treat a range of different conditions (e.g. haemor-
rhage, haematuria, gastric haemorrhage, microarterial trauma) so all studies were presented in
Retrospective HBA
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this case. (The other studies used a more homogenous range of methods and models to treat
single conditions.) Panel members were asked to independently categorise the overall impact
of the procedures employed for each of the 6 interventions as mild, moderate, or severe. Non-
recovery procedures were excluded where this was clear (Box 1).
Clinical relevance
Benefit was assessed in terms of clinical relevance. Clinical relevance was indicated by: i. con-
cordance / discordance between the findings from systematic reviews of animal and human
studies for the same interventions, with concordance suggesting that animal studies model the
human condition adequately[22], and ii. current clinical practice relating to the 6
interventions.
Data analysis
Extracted textual data were content analysed. Quantitative data were aggregated. The analysis
of harms and benefits was guided by Bateson’s Cube[3] (Fig 1). Bateson’s Cube was designed
to guide decision-making for authorising individual animal studies but in practice it has
Box 1. Severity categorised according to directive 2010/63/EU[1]
Mild
Procedures on animals as a result of which the animals are likely to experience short-
term mild pain, suffering or distress, as well as procedures with no significant
impairment of the well-being or general condition of the animals.
Moderate
Procedures on animals as a result of which the animals are likely to experience short-
term moderate pain, suffering or distress, or long-lasting mild pain, suffering or distress,
as well as procedures that are likely to cause moderate impairment of the well-being or
general condition of the animals.
Severe
Procedures on animals as a result of which the animals are likely to experience severe
pain, suffering or distress, or long-lasting moderate pain, suffering or distress, as well as
procedures that are likely to cause severe impairment of the well-being or general condi-
tion of the animals.
Non-recovery
Procedures which are performed entirely under general anaesthesia from which the ani-
mal shall not recover consciousness.
Retrospective HBA
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proved difficult to use prospectively.[2] We tested its use as a guide to conducting a retrospec-
tive HBA.
We used the most recent version of Bateson’s Cube which consists of 3 axes assessing ani-
mal suffering, the likelihood of benefit and the importance of research. (The axes on the origi-
nal version of the cube were animal suffering, certainty of medical benefit and quality of
research, respectively.) According to Bateson the ‘importance of research’ axis refers to both
research quality and conceptual advances unrelated to clinical benefit.[24] For this axis we use
Perel et al’s assessments of research quality, but we cannot ascertain whether the studies pro-
duced conceptual advances unrelated to clinical benefit. Citation scores, however, are able to
indicate the broad (not necessarily clinical) impact of the animal studies and are used as such
in this context. Box 2 shows the data used for each of the axes. According to Bateson, if the
three assessments fall into the solid part of the cube the project is unacceptable.[3]
Box 3 outlines the terminology used in this paper.
Results
Sample
Two hundred and twelve of the 228 papers reviewed by Perel et al[22] were obtained. Fifteen
papers, all on thrombolytic therapy for stroke, could not be traced despite the help of
Fig 1. Bateson’s cube.
https://doi.org/10.1371/journal.pone.0193758.g001
Box 2. Data for the 3 axes of Bateson’s cube
Animal suffering axis: extracted data on harms, expert panel severity classifications
Likelihood of benefit axis: concordance between animal and human studies, current
clinical practice
Importance of research axis: Perel et al’s assessment of research quality, citation scores
for the animal studies
Retrospective HBA
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experienced librarians. A further paper was excluded as it was a review. The references and
missing papers are listed in S1 File. References to the 228 animal studies.
Data extraction
Agreement between the 2 independent data extractors was very high for most items (average
93% agreement) except for the item on the number of animals used (79% agreement).
The studies
The United States was the most common location for the research, followed by Europe and
Japan (Table 1). Just over half the studies (52%) were conducted by universities, followed by
hospital and university collaborations (17%), pharmaceutical company collaborations (9%),
pharmaceutical companies alone (8%) and other institutes and collaborations (13%). They
span the years 1967 to 2005, with most studies conducted in the 1990s for all interventions
except for the bisphosphonate and thrombolytic studies, of which more were conducted in the
2000s than other decades. The studies involved an estimated 27,149 animals, including rats,
mice, guinea pigs, rabbits, pigs, non-human primates (baboons, monkeys, squirrel monkeys),
cats, sheep and cows. All studies used animals as models of human conditions, rather than for
regulatory purposes.
The animal studies were first published before human studies in the case of antifibrinoly-
tics, bisphosphonates and Tirilazad, at around the same time for antenatal corticosteroids, but
after human studies in the case of corticosteroids and thrombolytics (Table 2). In the case of
bisphosphonates, Tirilazad and thrombolytics, publication of animal studies continued after
the systematic reviews of the clinical trials were published.
Reporting
Reporting of animal harms and welfare was poor (Table 3) and the information reported
was basic. Reporting of animal numbers was poor, particularly for studies of antenatal
Box 3. Terminology
Interventions: the 6 different treatments being tested, i.e. antifibrinolytics, thromboly-
tics etc.
Studies: the 228 studies conducted to test the interventions
Experiments: one or more experiments may be conducted within individual studies
Procedures: the actions performed on animals during experiments, categorised for
severity as part of the HBA
Harms: the pain, suffering or distress animals may experience during, and/ or as a result
of, procedures
Animal model: where animals are used to ‘model’, or mimic, human conditions
Endpoint: the planned time for completion of the experiment, when animals are killed
(NB: these are not predefined humane endpoints)
Retrospective HBA
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corticosteroids, where foetuses might be studied in ‘batches’, with their tissues and blood
‘pooled’. Thirty two percent of all studies (n = 69) failed to report how animals were killed and
10% (n = 21) did not report when they were killed. Seventy percent (n = 148) failed to report
any welfare information and only 3 studies reported post-operative care (one simply men-
tioned that animals were given post-operative care, one reported use of analgesia and penicil-
lin, one reported that animals were monitored and released to gang cages). Thirteen percent of
studies (n = 27) failed to report use of anaesthesia and 97% (n = 206) did not report analgesia
Table 1. Study locations, numbers of animals and publication dates.
Location Institution Publication dates of studies
Antifibrinolytics
(8 studies)
USA 4; Sweden 2;
France 1; Switzerland 1
Universities 4; hospitals 2; pharmaceutical
company 1; hospital/ independent institute
collaboration 1
Total pharmaceutical or pharmaceutical
collaboration: 1 (12.5%)
1967–1997
(no mode, more studies conducted in 1990s than
other decades)
Bisphosphonates
(16 studies)
USA 6; Japan 3; Poland 2; China 2;
Italy 2; Brazil 1
Pharmaceutical and hospital / university
collaboration 5; pharmaceutical company 4;
university 4; hospital 1; hospital/ university
collaboration 1; centre for disease control 1
Total pharmaceutical or pharmaceutical
collaboration: 9 (56%)
1991–2005
(mode 2001, studies evenly distributed between
1990s and 2000s)
Corticosteroids
(17 studies)
USA 8; Israel 2; Turkey 2; Sweden 2;
Germany 1; Mexico 1; South Korea 1;
Taiwan 1
Universities 12; pharmaceutical companies 3;
hospital / university collaboration 1; hospital 1
Total pharmaceutical or pharmaceutical
collaboration: 3 (18%)
1975–2005
(mode 2005, although more studies conducted in
1990s than other decades)
Tirilazad
(18 studies)
Germany 7; USA 7; UK 1; Canada 1;
Sweden 1; South Korea 1; Japan 1;
Switzerland 1; Turkey 1
Universities 14; hospital 1; hospital / university
collaboration 2; pharmaceutical / university
collaboration 1
Total pharmaceutical or pharmaceutical
collaboration: 1 (5.5%)
1990–2004
(mode 1994, more studies conducted in 1990s
than other decades)
Antenatal
corticosteroids
(56 studies)
USA 47; Australia 7; Japan 3; Canada 2;
Sweden 1; Chile 1; Hungary 1; Italy 1;
Netherlands 1; Germany 1; Austria 1;
Finland 1
Universities 32; Hospitals 4; hospital /university
collaboration 17; university / primate centre
collaboration 1; pharmaceutical and hospital/
university collaboration 1; veterinary college 1
Total pharmaceutical or pharmaceutical
collaboration: 1 (2%)
1971–2004
(mode 1997, more studies conducted in 1990s
than other decades)
Thrombolytics
(97 studies)
USA 63; Japan 18; Germany 14;
Canada 4; France 4; Belgium 2; South
Korea 1; Turkey 1; Switzerland 1
Universities 45; hospitals 6; hospital / university
collaboration 16; pharmaceutical company 9;
pharmaceutical and university / hospital
collaboration 12; independent institute 7;
independent institute and university 1;
pharmaceutical and independent institute
collaboration 1
Total pharmaceutical or pharmaceutical
collaboration: 22 (23%)
1987–2005
(mode 2002, more studies conducted in 2000s
than other decades)
Total
(212 studies)
USA 135; Europe 53; Japan 25;
Canada 7; Australia 7; South Korea 3;
China 2; Israel 2; South America 2;
Mexico 1; Taiwan 1
Total 238 
Universities 111; hospital / university
collaboration 37; pharmaceutical and hospital/
university collaboration 19; pharmaceutical 17;
hospitals 15; independent institute 7;
independent institute and hospital/ university 2;
independent institute and pharmaceutical 1;
university / primate centre collaboration 1;
veterinary college 1; centre for disease control 1
Total pharmaceutical/ pharmaceutical
collaboration: 37 (17%)
All studies: 1967–2005
More studies conducted in 1990s than in other
decades for all interventions except for the
bisphosphonate studies, which were evenly
distributed between the 1990s and 2000s, and
the thrombolytic studies, of which more were
conducted in the 2000s than in other decades
 Hospitals include medical centres
Several studies involved international collaborations so country totals are greater than the total number of studies
https://doi.org/10.1371/journal.pone.0193758.t001
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use. Half of all studies made no ethical statement. Thirty nine studies (18%) reported addi-
tional procedures involving further animals but gave little information on the animal numbers
or procedures involved. See S1 Table. Additional procedures involving further animals.
Harms
Much of the data presented below is summarised in Table 3 above and Tables 4, 5 and 6 below.
Table 5 summarises the severity assessments. Detailed scoring for each severity assessment is
available in S2 Table. Results of expert panel severity classifications.
Table 2. Comparison of dates of animal and human studies.
Publication
dates
of animal
studies
Publication
dates
of human
studies
Date of clinical systematic review/
meta-analysis
Number of animal studies conducted after treatment effect
known in humans
Antifibrinolytics
(8 studies)
1967–1997 1987–1998 1999 None
Bisphosphonates
(16 studies)
1991–2005 1995–1999 2002 4 studies (1 in 2003; 2 in 2004; 1 in 2005)
Corticosteroids
(17 studies)
1975–2005 1972–2005 2005 None
Tirilazad
(18 studies)
1990–2004 1994–1997 2001 3 studies (2 in 2003; 1 in 2004)
Antenatal
corticosteroids
(56 studies)
1971–2004 1972–2002 2006 None
Thrombolytics
(97 studies)
1987–2005 1981–2002 2004 4 studies (all in 2005)
https://doi.org/10.1371/journal.pone.0193758.t002
Table 3. Reporting (n = studies apart from final column).
No ethical
statement
reported
Use of
anaesthesia not
reported
How animals killed not
reported
Time of death (post
experiment) not
reported
Use of
painkillers not
reported
No welfare
information
reported
Total number
animals used
Antifibrinolytics
(n = 8 studies)
6 (75%) 0 7 (87%) 3 (37%) 7 (87%) 5 (62%) 668
Bisphosphonates
(n = 16)
8 (50%) 4 (25%) 7 (44%) 0 16 (100%) 2 (12%) 807
Corticosteroids
(n = 17)
13 (76%) 0 5 (29%) 3 (18%) 16 (94%) 9 (53%) 2296
Tirilazad
(n = 18)
10 (56%) 0 3 (17%) 1 (5%) 16 (89%) 12 (67%) 764
Antenatal
corticosteroids
(n = 56)
38 (68%) 14 (25%) for
caesarean section
12 (21%) for
neither mother
nor foetus
12 (21%)
[10 = foetal manner of death
unreported, (including 1
maternal), plus 2 = maternal
only]
4 (7%) [foetuses]
0 (0%) of 11
55 (98%)
[mothers]
56 (100%)
[foetuses]
41(73%)
[mothers]
56 (100%)
[foetuses]
16,000
(both
mothers and
neonates)
Thrombolytics
(n = 97)
30 (31%) 11 (11%) 35 (36%) 10 (10%) 96 (99%) 79 (81%) 6614
Total (n = 212) 106 (50%) 27 (13%) 69 (32%) 21 (10%) 206 (97%) 148 (70%) 27,149
 Only 11 of the antenatal corticosteroid studies reported that mothers were killed.
 Total number of animals used in corticosteroid studies likely to be an underestimate due to the poor reporting of animals excluded from studies
Estimated number
https://doi.org/10.1371/journal.pone.0193758.t003
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Antifibrinolytics for haemorrhage. There were 8 studies of antifibrinolytics (aprotinin,
aminocaproic acid and tranexamic acid) using various models of blood loss. Six hundred and
sixty eight animals were used (485 rats, 109 rabbits, 74 pigs) with an average 83 animals per
study. Anaesthesia was reported in all studies. Four models induced blood loss in rats, rabbits
or pigs by cutting the ear or tail, with endpoints ranging from 2 hours to 6 days. Two models
induced gastric bleeding in rats, one by pouring hydrochloric acid solution into rats’ stomachs
and the other by creating mucosal lesions in the stomach. Animals were killed at the end of
these experiments or after 6 hours. Two models induced blood loss through surgical injury to
the internal organs: the first inflicted renal injuries on rabbits by stabbing, crushing, cutting or
punch biopsy, with rabbits followed up for 5–10 days, during which they were housed individ-
ually in metabolic cages. The second inflicted liver injuries on pigs by applying a clamp to the
lobes of the liver. This study reported the use of restraints and paralytics in addition to painkill-
ers and anaesthesia, with the endpoint either death or four hours. Only one study reported
how animals were killed and half (n = 4) reported the experimental endpoint. No deaths before
endpoint were reported. It was seldom clear how long anaesthesia was maintained for and con-
sequently it was difficult to determine what animals experienced, or for how long. No unex-
pected events were reported. Only one study reported using painkillers. Three studies (38%)
reported welfare information (access to food and water / metabolic cage use). None gave
details of post-operative care. Six (75%) did not make an ethical statement.
These studies were mostly scored as moderate or mild, except for the study that involved
renal injuries to rabbits with endpoints of up to 10 days, which was mostly scored as severe.
Two studies may have been non-recovery but as this was unclear they were scored, mostly as
severe.
Table 4. Reported methods of killing animals (n = number of studies).
Antifibrinolytics
(n = 8)
Air emboli: n = 1; not reported: n = 7
Bisphosphonates
(n = 16)
Exsanguination: n = 4; CO2 inhalation: n = 3; cardiac puncture: n = 1; euthanasia agent
(‘Tanax’): n = 1; not reported: n = 7
Corticosteroids
(n = 17)
Decapitation: n = 6; CO2 inhalation: n = 1; euthanasia agent (potassium chloride): n = 1;
perfusion fixation: n = 1; aorta and pulmonary artery cut: n = 1; rapid freezing (liquid
nitrogen): n = 1; left to die: n = 1; not reported: n = 5
Tirilazad (n = 18) Perfusion fixation: n = 8; euthanasia agent (potassium chloride): n = 3; anaesthesia
overdose (pentobarbital): n = 1; rapid freezing (liquid nitrogen): n = 1; decapitation:
n = 1; exsanguination: n = 1; not reported: n = 3
Antenatal
corticosteroids
(n = 56)
FoetusesTracheal blockage (trachea clamped 15, endotracheal tube plugged / clamped 4):
n = 19; anaesthesia overdose (pentobarbital 12; phenobarbital 1): n = 13; left to die: n = 6;
euthanasia agent (lidocaine): n = 5; decapitation/severing of cervical cord: n = 5;
strangulation: n = 4; suffocation: n = 1. Mothers (11/56 studies reported mothers were
killed) Anaesthesia overdose (pentobarbital 4; diethyl ether 1): n = 5; decapitation: n = 2;
thoracotomy: n = 1
Not reported (foetal and/or maternal): n = 12
Thrombolytics (n = 97) Perfusion fixation: n = 20; anaesthesia overdose (pentobarbital 17; thiamyl sodium 1;
thiopental 2): n = 20; decapitation: n = 8; exsanguination: n = 4; rapid freezing: n = 3;
euthanasia agents (‘potassium chloride 3, ‘Terminal’ 1, KAX cocktail 1): n = 5; brains
removed: n = 3; C02 inhalation: n = 2; missing: n = 1; not reported: n = 35
Total (n = 212) Anaesthesia overdose: n = 39; perfusion fixation: n = 29; decapitation: n = 22; tracheal
blockage: n = 19; euthanasia agent: n = 15; exsanguination: n = 9; left to die: n = 7; CO2
inhalation: n = 6; rapid freezing: n = 5; miscellaneous (air emboli, aorta and pulmonary
artery cut, cardiac puncture, suffocation, thoracotomy): n = 5; strangulation: n = 4; brains
removed: n = 3; missing: n = 1; not reported: n = 69
 Studies could use more than one means of death
https://doi.org/10.1371/journal.pone.0193758.t004
Retrospective HBA
PLOS ONE | https://doi.org/10.1371/journal.pone.0193758 March 28, 2018 10 / 26
Table 5. Summary results of severity assessment by expert panel.
Animal model Summary of scorers’ assessments Final summary
Antifibrinolytics to promote blood
clotting and control bleeding
The study of the shortest duration (2-6h) was generally
assessed as moderate, with two scoring it as mild. The study
lasting 24 hours had a spread of scores from mild, through
moderate to severe, two scoring moderate on condition that
bleeding was limited and analgesia given. Studies lasting
5–10 days: the first involved cutting the tail under
anaesthesia and again produced a spread of scores from mild
through moderate to severe. The study that involved rabbits
having renal injuries inflicted under anaesthesia with 5–10
day follow up was mostly scored as severe.
Studies scored from mild to severe
Bisphosphonates to slow down /prevent
bone loss
Most scorers felt the general model was of moderate severity,
but rising to the severe category as the duration of the study
increased and if no analgesia was used. One scorer
consistently categorised procedures as less severe than other
scorers for this study.
Mostly moderate, some severe
Corticosteroids to reduce intracranial
pressure after traumatic brain injury
In general this model was scored as severe. In cases where
animals were not anaesthetised or only lightly anaesthetised
all scorers categorised procedures as severe. Endpoints were
from 2h up to 30 days. Most endpoints were categorised as
severe except for studies of the shortest duration which two
scorers categorised as moderate as long as anaesthesia was
used. For studies lasting 2–4 weeks all but one scorer
categorised harms as severe.
Mostly severe
Tirilazad to protect brain tissue after
stroke
The overall model was categorised as severe. Variations of
the model were all categorised as severe, except for one study
that reported post-operative analgesia; this was categorised
as generally severe still, but potentially as less severe.
Severe
Antenatal corticosteroids to reduce
neonatal mortality and morbidity in
preterm babies
For the overall model scorers categorised harms to the
mother as moderate to severe, depending on use of
analgesia/ anaesthesia. For the overall model the scorers
categorised harms to the foetus as generally severe,
particularly if the foetus survived beyond birth and had no
anaesthesia/ analgesia. For the administration of drugs to the
mother scorers generally categorised this as moderate to
mild. For the administration of drug to neonates after
delivery, scorers categorised this as severe, particularly if
neonates not anaesthetised. For administration of the drug
to the foetus in utero scorers categorised the procedures to
the foetus as severe if no anaesthesia was used (otherwise
mild), and moderate to severe for the mother. For
administration of the drug via the mother this was
categorised as moderate to severe for the mother and
moderate to severe for the foetus. For neonates having
mechanical ventilation after delivery scorers categorised this
as severe, or moderate if anaesthesia was used. In terms of
endpoints, scorers categorised harms for those killed in utero
and at delivery as moderate; as moderate to severe for deaths
post-delivery (30 mins to 6 days), with increasing severity
scores as time post-delivery increased. Harms to neonates
left to die with no endpoint were categorised as severe by 5/6
scorers (animals found dead should automatically score as
‘severe’). Neonates having ventilation were scored as
experiencing moderate to severe harms unless they were
anaesthetised, with severity scores increasing with the
amount of time spent on the ventilator.
Foetuses and neonates: mostly moderate to severe
Mothers: mostly moderate to severe. Some maternal
procedures scored as mild (e.g. maternal drug
administration) but these were within overall models
scored as moderate to severe.
(Continued)
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Bisphosphonates for osteoporosis. There were 16 studies of bisphosphonates (mainly
alendronate), involving 807 animals (56 baboons, 751 rats) with an average 50 animals per
study. The model consisted of ovariectomy followed by drug treatment (usually by oral
gavage). Some animals had additional procedures at regular intervals, such as blood and urine
tests, bone mineral density measurements, scans and x-rays. Twelve studies (75%) reported
using anaesthesia for ovariectomies and/ or additional procedures. Nine studies (56%)
reported how animals were killed. All studies reported endpoints, ranging from 4 weeks to 2
years. One study reported deaths prior to endpoint. No unexpected events were reported. No
studies reported using paralytic agents. None reported using painkillers. Fourteen studies
(88%) reported welfare information (housing/ metabolic cage use/ temperature and lighting
Table 5. (Continued)
Animal model Summary of scorers’ assessments Final summary
Thrombolytics (tissue plasminogen
activator, or tPA) to dissolve clot/ improve
blood flow after stroke
In general scorers categorised the stroke model as severe.
Some commented that if anaesthesia/ analgesia were used
and duration of study brief, then studies might score less
severely. Scorers categorised studies that induced stroke
while animals were awake as severe. Most categorised
relatively short term studies (up to 33h) that induced stroke
under anaesthesia as severe. Most categorised studies that
induced stroke under anaesthesia and then involved repeated
MRI scans as severe.
Mostly severe
https://doi.org/10.1371/journal.pone.0193758.t005
Table 6. Summary of harms.
Endpoint
range
No.
studies
reporting
deaths before
endpoint
Noteworthy harms reported Total no.
animals
(species)
Average
no.
animals
per study
No. studies
reporting
welfare
information
No. studies
reporting
ethical
statement
Severity
classification by
expert panel
Antifibrinolytics
(8 studies)
4 hrs– 10
days
0 668 (rats,
rabbits, pigs)
83 3 (38%) 2 (25%) Ranged from mild
to severe
Bisphosphonates
(16 studies)
4 weeks– 2
years
1 (6%) 807 (rats,
baboons)
50 14 (88%) 8 (50%) Mostly moderate,
some severe
Corticosteroids
(17 studies)
2 hrs– 30
days
9 (53%) Some animals had no or only
light anaesthesia prior to
restraint and head injury. Some
animals left to die of injuries.
2296 (mice,
rats, guinea
pigs, cats,
monkeys)
135 8 (47%) 4 (24%) Mostly severe
Tirilazad
(18 studies)
3 hrs– 7
days
3 (17%) Some iatrogenic deaths. Many
animals had repeated daily
assessments post-surgery,
suggesting cumulative harms
764 (rats,
rabbits, cats)
42 6 (33%) 8 (44%) Severe
Antenatal
corticosteroids
(56 studies)
0 hrs– 6
days
(neonate)
20 (36%) Most studies did not report
neonatal anaesthesia. Some
neonatal upper airway leaks
during tracheal tube placement,
also pneumothoraces. Some
neonates left to die.
16,000,
(mothers,
neonates)
Sheep, rabbits,
rats, monkeys,
baboons, cows
286 Mothers 15
(27%)
Foetuses 0
18 (32%) Mostly moderate
to severe for both
mothers and
neonates
Thrombolytics
(97 studies)
6 hrs– 2
months
37 (38%) Some animals had stroke
induced while conscious and
restrained / paralysed. Many
had repeated daily assessments
and scans, suggesting
cumulative harms.
6614 (rats,
rabbits, mice,
guinea pigs,
squirrel
monkeys,
baboons)
68 18 (19%) 67 (69%) Mostly severe
https://doi.org/10.1371/journal.pone.0193758.t006
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/diet and access to water). None gave details of post-operative care. Half made an ethical
statement.
This model was mostly scored as moderate, rising to the severe category as the duration of
studies increased.
Corticosteroids for brain injury. There were 17 studies of corticosteroids (mainly meth-
ylprednisolone, dexamethasone, betamethasone), involving 2296 animals (1163 mice, 863 rats,
210 guinea pigs, 31 monkeys, 29 cats), with an average 135 animals per study. The model
involved inflicting brain injury on animals and testing the effect of corticosteroids on recovery.
The most common way of inducing brain injury (14 studies) was to use stunners or devices
designed to drop weights or protruding rods onto restrained animals’ heads. Some animals
had steel caps fitted to their skulls, or holes drilled in their skulls prior to injury. In two studies
injury was inflicted during brain surgery and in another monkeys were attached to a sled that
crashed at speed. In 3 studies animals were not anaesthetised and in 2 studies only lightly
anaesthetised. No studies reported using painkillers; one reported that analgesics ‘appeared
unnecessary’. No studies reported using paralytics. Animals were reported to die upon impact
in 8 studies (47%), accounting for an estimated 10–18% of animals in these studies. One study
reported post-operative wound infections in 2 animals. Animals were observed for varying
lengths of time post injury and some were tested for neurological status and grip using a string
test. Fourteen studies (82%) reported endpoints, ranging from 2 hours to 30 days. Nine studies
(53%) reported deaths prior to endpoint. Twelve studies (71%) reported how animals were
killed; in one study animals were left to die of their injuries. Eight studies (47%) gave welfare
information (diet/ access to water). One study mentioned post-operative care. Most studies
(76%) made no ethical statement.
This model was mostly scored as severe. All scorers categorised procedures as severe where
animals had no or only light anaesthesia. Most endpoints were categorised as severe except for
studies of the shortest duration which two scorers categorised as moderate as long as anaesthe-
sia was used. For studies lasting 2–4 weeks all but one scorer categorised harms as severe.
Tirilazad for stroke. There were 18 studies of Tirilazad, involving an estimated 764 ani-
mals (25 cats, 111 rabbits, at least 628 rats), with an average of at least 42 animals per study.
The model involved an operation under anaesthesia to occlude the middle cerebral artery
(MCA) and subsequent testing of the effect of Tirilazad on recovery. During the operation
probes and monitors could be placed on the brain. In some studies hypothermia was also
induced. Seven studies (39%) occluded the MCA using monofilament. Animals were usually
given Tirilazad intra-peritoneally or intravenously at various time points (up to 24h) post-
operatively. Anaesthesia was reported in all 18 studies. Two studies reported using analgesia.
One reported using a paralytic agent.
There were 2 broad categories of experiment: i. animals had an operation to occlude the
MCA, were given Tirilazad and killed up to 24 hours post-operatively. These experiments
tended to involve more surgical procedures; ii. animals had an operation to occlude the MCA,
were given Tirilazad and then had daily assessments, with death up to 3 days post-operatively,
or at 7 days. Post-operative assessments included MRI scans at 24 hours (under anaesthesia),
attempts to arouse animals using tactile and painful stimulation up to 24h post-operatively
and daily neurological assessments using methods that included pulling animals’ tails and
pushing them to test resistance.
Fifteen studies (83%) reported how animals were killed. Seventeen (94%) reported end-
points, ranging from 4 hours to 7 days. Three (17%) reported deaths before endpoint. In one
study involving craniectomy and removal of the eye, 5 animals died up to 2 days post-opera-
tively. Six of the 7 studies that occluded the MCA using a monofilament reported that animals
suffered vessel perforation and consequent subarachnoid haemorrhage; 29 animals were
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‘excluded’ for this reason. Information relating to welfare was given in 6 studies (33%), mainly
relating to pre-operative fasting. One study reported post-operative care, noting that animals
were given analgesia and penicillin. Ten studies (56%) made no ethical statement.
All variations of the model were categorised as severe. A variation that reported post-opera-
tive analgesia was still categorised as severe, but as potentially ‘less severe’.
Antenatal corticosteroids for neonatal respiratory distress. There were 56 studies of
antenatal corticosteroids (mainly betamethasone, dexamethasone, hydrocortisone) involving
an estimated 16,000 animals (2,665 mothers and 13,335 neonates). Of the mothers 1057 were
sheep, 727 rats, 699 rabbits, 117 monkeys, 45 cows and 20 baboons. The average number of
animals used per study (both mothers and neonates) was estimated at 286. One or more of the
following methods were used to administer antenatal corticosteroids: i. administration to preg-
nant mothers over several weeks before preterm delivery of their neonates. ii. administration
to foetuses in utero via injection, laparotomy, intra-amniotic injection or ultrasound-guided
foetal injection. iii. administration to foetuses in utero, where mothers were given a hysterot-
omy and catheters (including tracheal catheters) were placed in foetuses, passing from the
uterus through an incision in the mother to her flanks, with drugs delivered for up to 14 days
and tracheal fluids withdrawn from some foetuses. iv. administration to neonates after delivery
via injection or an endotracheal tube.
Mothers had caesarean section (CS) for preterm delivery of their neonates, after which their
neonates were removed. Thirty five studies (62%) reported maternal anaesthesia for CS deliv-
ery. Fourteen studies (25%) did not report anaesthesia for CS delivery and 2 studies (4%)
reported that no anaesthesia was used (one used sedation only and another reported stretching
animals, covering their eyes and removing stitches from a previous operation to deliver neo-
nates). In 5 studies (9%) the mother was killed prior to CS. In addition to CS, further proce-
dures for mothers could include ultrasound scans, amniocentesis, hysterotomy, foetal
injections, laparotomy, blood sampling and administration of antibiotics or progesterone.
Maternal anaesthesia was reported for additional procedures in 13 studies but not in 11 studies
where similar procedures were conducted. In 12 studies (21%) anaesthesia was reported for
neither the mother nor the foetus/ neonate. The use of maternal analgesia was reported in only
one study. Seventy nine percent of studies (n = 44) did not report the fate of mothers. Twenty
percent (n = 11 studies) reported that mothers were killed before or around CS, including 8
that reported manner of death. One study reported that mothers (baboons) were released back
to gang cages.
After delivery neonates were either killed or observed for varying lengths of time (up to 6
days). For ventilation studies neonates had endotracheal tubes placed at delivery and were
mechanically ventilated for periods ranging from 15 minutes to 24 hours, after which they
were killed. Some were given pentobarbital to prevent spontaneous respiration. Some had
their tracheas clamped during or after ventilation. Some had catheters inserted, some had
agents delivered via intra-tracheal instillations and some had lung fluids aspirated. Foetal /
neonatal anaesthesia was reported in 18 studies (32%) but in 25 studies where neonates sur-
vived for a period after delivery no anaesthesia was reported, including studies that involved
ventilation and placement of catheters and endotracheal tubes. No anaesthesia was reported
for foetuses undergoing placement of catheters in utero. Four studies (7%) reported using a
paralytic agent in neonates, including 2 for which no anaesthesia was reported. No neonatal
analgesia was reported.
Neonates/ foetuses were either killed in utero, at delivery, at various time points post-deliv-
ery (5 minutes—6 hours), or after various periods of ventilation (15 minutes—24 hours) or
observation (1 to 6 days post-delivery). In 4 studies (7%) neonates were observed to see how
long it took them to die post-delivery. Ten studies (18%) did not report how neonates were
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killed and four (7%) did not report when they were killed. Twenty studies (36%) reported
deaths before endpoint, including abortions, dead or macerated foetuses in utero, stillbirths
and early postnatal deaths. Fifteen studies (27%) reported at least one unexpected event,
including pneumothoraces (involving at least 38 neonates), upper airway leaks during tracheal
tube placement (7 neonates), pulmonary interstitial emphysema, oedematous foetuses, prema-
ture delivery and mothers not pregnant. No studies provided welfare information about neo-
nates. Fifteen studies (27%) reported information about maternal welfare (animal handling,
housing, access to food and water, mating, transportation, stress), including one that gave
information on post-delivery care. Thirty eight studies (68%) made no ethical statement.
For both mothers and neonates the models were mostly scored as moderate to severe.
Thrombolytics for stroke. There were 97 studies of thrombolytics (tissue plasminogen
activator, tPA) involving an estimated 6614 animals (3484 rats, 2701 rabbits, 246 mice, 120
guinea pigs, 33 squirrel monkeys, 30 baboons), with an average 68 animals per study. (Two
studies did not report numbers so the actual number is higher.) This model involved inducing
a stroke and testing the effect of a thrombolytic agent on recovery. On the day before the
experiment some animals underwent preparatory surgery under anaesthesia to fabricate a clot,
or to place catheters, ligatures or probes. On the day of surgery animals were anaesthetised and
a stroke was induced by blocking the carotid and/or cerebral arteries with clots or filaments, or
by tying the arteries. During surgery some animals had their skulls opened for the placement
of probes and monitors. They were given the thrombolytic agent intravenously. In a variation
of the model (11 studies) animals had surgery under anaesthesia to place a catheter, then after
recovering from anaesthesia a clot was injected through the catheter to induce a stroke whilst
the animals were conscious (and restrained). Anaesthesia was reported in 73 studies (75%). In
13 studies (13%) anaesthesia was reported for some procedures / animal groups but not all and
in 11 studies (11%) no anaesthesia was reported. The use of paralytic agents was reported in 6
studies, five in which animals were anaesthetised and one in which baboons had a stroke
induced whilst awake. Analgesia was reported in one study.
Post-surgical observation periods could be relatively short (2–24 hours), or could last up to
2 weeks or 2 months. Post-stroke animals frequently had reduced levels of spontaneous activ-
ity, rapid involuntary movements of the eye, inability to stand, severely uncoordinated move-
ments and hemiparesis. Some had neurological assessments over 1–4 hours, 1–2 days, or for
up to 1 week. Assessments commonly involved being held upside down by the tail or being
pushed laterally to test resistance. Others included determining how long rats could remain on
a horizontal suspended rotating rod, or how long it took them to remove sticky tape from their
paws. Some animals had angiograms, CT or MRI scans post-stroke. For MRI scans animals
might be restrained in a head holder with bars in their ears. Anaesthesia appeared to be main-
tained for scans but this was not always clear. MRI scans could continue for up to 8 hours post
stroke, or could be performed at 1, 2 or 7 days.
Sixty two studies (64%) reported how animals were killed and 90% (n = 87) reported when
they were killed. Endpoints ranged from up to 6 hours to 2 months, with the most common
endpoint being 24 hours post stroke, reported in 35 studies (36%). Nineteen studies (20%)
reported endpoints of one week or longer. Thirty seven studies (38%) reported deaths prior to
endpoint, mainly in the first 24 hours post-stroke. The causes included haemorrhage, cerebral
oedema and ‘technical reasons’. Seventeen studies (18%) reported some type of unexpected
event including technical difficulties, failure of procedures, haemorrhage, major bleeding com-
plications, secondary stroke and fatal hypotension. Only 18 studies (19%) reported informa-
tion on welfare (housing/ temperature and light / access to food and water/ animal purchase /
monitoring of experiments / depth of anaesthesia), including one study that noted attempts to
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attenuate suffering. None gave details of post-operative care. Sixty seven studies (69%) made
an ethical statement.
Most scorers categorised the stroke models as severe. Some commented that if the study
duration was brief and anaesthesia/ analgesia were used, then studies might score less severely.
Scorers categorised models that induced stroke while animals were conscious as severe.
Manner of death (all interventions). Sixty eight percent of studies (n = 145) reported
how animals were killed. The most frequently used method was an overdose of anaesthesia but
a wide variety of additional methods were employed. In 7 studies (6 of which were for antena-
tal corticosteroids) animals were left to die. Methods of death for foetuses included tracheal
blockage, strangulation and suffocation.
Summary of harms. Most of the studies involved severe or mostly severe harms to ani-
mals, as indicated both by the data extracted on procedures and the severity classification by
the expert panel. As the extracted data support the severity classifications (Table 6) we have
used the latter when conducting the HBA.
The only studies that involved mostly moderate harms were those on bisphosphonates. A
greater percentage of bisphosphonate studies reported welfare information than other inter-
ventions and these studies also reported relatively few deaths before endpoint. Bisphosphonate
studies may have involved the least harms for animals.
Clinical relevance
As noted above, clinical relevance is indicated by concordance between the findings of ani-
mal and human studies for the same treatment intervention, and current clinical practice.
Antifibrinoloytics reduce surgical bleeding and the need for transfusion in humans and are
widely used in current clinical practice;[25] however the animal studies produced inconclu-
sive data.[22] Bisphosphonates increase bone mineral density in animals and in post-meno-
pausal women with osteoporosis.[22] They are recommended as a primary preventative
treatment for post-menopausal women with osteoporosis.[26] Corticosteroids benefit ani-
mals with head injury but increase the risk of mortality in humans.[22] They are no longer
recommended for routine use in people with traumatic head injury.[27] Tirilazad reduces
infarct volume and improves neuro-behavioural scores in animals but increases the risk of
death and dependency in humans.[22] It is considered to have no role in the current treat-
ment of stroke.[28] Antenatal corticosteroids reduce respiratory distress in both animal and
human neonates. They also reduce mortality in humans but the mortality data were incon-
clusive in animals.[22] The routine clinical use of antenatal corticosteroids for preterm
delivery is recommended in hospital settings in high income countries.[29] Thrombolytics
reduce infarct volume and improve neuro-behavioural scores in animals but increase haem-
orrhage risk; in humans they reduce death or dependency despite an increase in haemor-
rhage.[22] Thrombolytics are used to treat certain categories of ischaemic stroke as long as
patients present up to 4.5 hours post-stroke (ideally within 3 hours) and relevant expertise
and infrastructure is available,[30, 31] however there has been some controversy over their
use.[32–34]
Concordance appears to relate to clinical use, with fully and partially concordant treatment
interventions being in clinical use (see Table 7). This suggests that concordance is a good indi-
cator of clinical relevance. Fully concordant interventions (bisphosphonates, thrombolytics)
also used relatively low numbers of animals (Table 6) and a greater percentage of studies in
fully concordant interventions also made ethical statements (Table 3) and had pharmaceutical
company involvement (Table 1) than other interventions. Studies for these interventions were
also conducted more recently (Table 1).
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Research importance
As noted above, research importance refers to the quality of the research as well as its broader
impact (indicated here by citation scores). Perel et al rated the quality of research as ‘poor’ for
studies across all 6 interventions. The average citation scores for the studies ranged from 10 for
antifibrinolytics to 76 for bisphosphonates (Table 8), with 50 being the average for all studies.
The citation scores appeared to track clinical relevance, with the two highest scores being
for the fully concordant interventions, bisphosphonates and thrombolytics (Table 9).
Retrospective harm-benefit analysis
As noted above, if the three assessments (animal suffering, likelihood of benefit, research
importance) fall into the solid part of Bateson’s Cube, the project is deemed unacceptable. We
performed the HBA by conducting the three assessments for each of the six treatment inter-
ventions (Fig 2).
For the studies of corticosteroids and Tirilazad there was high animal suffering and low
(no) clinical benefit. Their research importance is considered to be low since the quality of
research was poor and their citation scores were below average. As such these studies fall into
the solid part of the cube and should not have been approved. The thrombolytic studies
involved high animal suffering. Their research importance is considered to be medium since
although the research quality was poor, their citation scores were above average. Due to con-
troversy regarding the use of thrombolytics, as well as the conditions placed upon their use,
their clinical benefit is considered to be medium to high. Because of the high animal suffering
these studies fall into the solid part of the cube and should not have been approved. The
Table 8. Citation scores.
Intervention No. studies Total no. citations Average citation score Research quality
Antifibrinolytics 8 83 10 Poor
Bisphosphonates 16 1213 76 Poor
Corticosteroids 17 610 36 Poor
Tirilizad 18 820 45 Poor
Antenatal corticosteroids 56 2483 44 Poor
Thrombolytics 97 5370 55 Poor
https://doi.org/10.1371/journal.pone.0193758.t008
Table 7. Clinical relevance.
Concordance In clinical use
Antifibrinolytics Discordance: animal data inconclusive but outcomes improved in
humans
Yes: widely used in clinical practice
Corticosteroids Discordance: improve outcomes in animals but increase mortality
in humans
No: no longer routinely recommended for traumatic head injury
Tirilazad Discordance: improves outcomes in animals but increases mortality
in humans
No: considered to have no role in the treatment of stroke
Antenatal
corticosteroids
Partial concordance: reduces respiratory distress in both animals
and humans; reduces mortality in humans but animal mortality data
inconclusive
Yes: routine use in hospitals in high income countries is recommended
Thrombolysis Concordance: improves outcomes in animals and humans but with
risk of haemorrhage
Yes: recommended for use with certain stroke patients if they present
within 4.5 hours post stroke and if relevant expertise is available. Use has
been considered controversial.
Bisphosphonates Concordance: improves outcomes in animals and humans Yes: recommended as primary preventative treatment for post-
menopausal women with osteoporosis
https://doi.org/10.1371/journal.pone.0193758.t007
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bisphosphonate studies involved mostly moderate, but also some severe, harms. As such they
are considered to involve medium and high animal suffering. The research importance for the
bisphosphonate studies is considered to be medium because although the citation scores were
well above average, the quality of research studies was poor. The clinical benefit of these studies
is considered to be high. As such the studies involving moderate suffering fall into the clear
part of the cube and were permissible, while those involving severe suffering fall into the solid
part and were not permissible.
It was not possible to assess concordance where animal studies had produced inconclusive
data, and as concordance was a necessary component of clinical relevance, it made the HBA
impossible. Consequently, it was not possible to conduct a HBA for antifibrinolytics, as the
data from the animal studies were inconclusive. However the fact that the animal data were
inconclusive, combined with the studies’ poor research quality and very low citation scores,
suggests that the clinical use of antifibrinolytics may have developed independently of the ani-
mal studies. In the case of antenatal corticosteroids, mortality data from the animal studies
were inconclusive but there was concordance between the animal and human studies in terms
of reducing neonatal respiratory distress. The antenatal corticosteroid studies involved mostly
moderate to severe harms for both mothers and neonates. As such they are considered to
involve high and medium animal suffering. The research importance for the antenatal cortico-
steroid studies is considered to be low because their research quality was poor and citation
scores are below average. Consequently, despite the clinical benefit of these studies being con-
sidered high (not counting the inconclusive mortality data), they fall into the solid parts of the
cube and were not permissible.
Table 9. Citation scores related to clinical relevance.
Concordance In clinical use Average citation score
Antifibrinolytics Discordant Yes 10
Corticosteroids Discordant: No 36
Tirilazad Discordant: No 45
Antenatal corticosteroids Partially concordant: Yes 44
Thrombolysis Concordant: Yes 55
Bisphosphonates Concordant: Yes 76
https://doi.org/10.1371/journal.pone.0193758.t009
Fig 2. HBA using Bateson’s cube.
https://doi.org/10.1371/journal.pone.0193758.g002
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The moderate bisphosphonate studies then, are the only studies that fall into the clear part
of the cube in that they were of medium research importance, appeared to minimise harms to
animals and were associated with benefits for humans.
Discussion
Study limitations
Despite expert help we were unable to find 15 of the original studies, all of which reported
research on thrombolytics. However, as the thrombolytic studies were by far the most numer-
ous and because we located the majority of them (n = 97), we are confident that the missing
papers did not bias our findings. Furthermore, the thrombolytic studies were homogenous in
terms of models used so the missing papers were unlikely to have presented any unusual
findings.
This is a re-analysis of an existing study so any limitations in the original study design are
reproduced here. Although the sample of interventions was not random it provided a range,
both in terms of interventions and in the spread of concordance, discordance and partial con-
cordance. As such it provides a good testing ground for analysing harms and benefits and is
appropriate for the purposes of this study. The methodological quality of the animal studies
for all 6 interventions was poor; this is not unusual for animal studies[35–39] but it may
explain why some of the animal data were inconclusive.
It is possible that the severity classifications could reflect poor reporting of measures taken
to alleviate suffering. Members of the scoring panel noted that in the absence of information
about analgesia, or duration of anaesthesia, they had to classify some procedures as severe that
may potentially have scored less severely. However, it is likely that the classifications reflect
actual harms since evidence suggests, for example, that if pain relief is not reported then it was
not administered.[40] The classification system itself is not very discriminating and although
other systems exist for classifying harms,[41] this one was chosen because it is used by EU reg-
ulatory bodies and is similar to the American system.[23]
In terms of exploring concordance between animal and human studies it is important to
note that many variables may influence the outcome of both animal and human studies,
including research design and reporting and publication bias. Perel et al, for example, found
strong evidence of publication bias in their systematic review of animal studies of thromboly-
tics which may have resulted in the treatment effects of thrombolytics being overestimated.
Consequently there is a need for caution when interpreting concordance. Furthermore, con-
cordance does not imply causation, i.e. while it may provide an indication of clinical relevance,
it does not necessarily imply that the animal studies led directly to human benefit. Indeed the
publication dates of the studies suggest that clinical trials did not follow on directly from ani-
mal studies; the animal and human studies often appeared to run concurrently and in some
cases human studies preceded animal studies, while in others animal studies continued to be
published after the treatment effect was known in humans (see Table 2). This confusing pic-
ture suggests a lack of communication between those conducting animal research and those
running clinical trials.[22]
Feasibility
We have confirmed the feasibility, both of conducting a retrospective HBA and of collecting
data on animal harms from pre-clinical research publications. We found Bateson’s cube to be
helpful in guiding the HBA as the principle is clear, namely that research falling into the solid
parts of the cube should not be approved. As such it follows a strict principle of disallowing
research that is of poor quality or that causes severe suffering.
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Harms
The studies involved an estimated 27,149 animals, including non-human primates. The most
common assessment of animal harms by the expert panel was ‘severe’. Reported use of analge-
sia was rare and some animals (including most neonates) endured significant procedures with
no, or only light, anaesthesia reported. Some animals suffered iatrogenic harms. Many were
kept alive for long periods post-experimentally but only 1% of studies reported post-operative
care. A third of studies reported that some animals died prior to endpoints.[1] Directive 2010/
63/EU (Annex IV) specifies acceptable and unacceptable methods for killing different species
of animals, indicating that some of the ways animals in these studies were killed would no lon-
ger be considered acceptable.[1] Severe harms however, continue to be permitted within cur-
rent regulatory frameworks; both Directive 2010/63/EU[1] and current US policy[23] allow
severe unalleviated pain, suffering or distress, although it requires strong justification. EU
requirements in 2014 to record actual, as well as predicted, harms[42] and to retrospectively
assess individual projects categorised as severe may eventually lead to greater adoption of
refinement measures, but there is still clearly an urgent need to review regulations that permit
animals to suffer severe harms. In the UK the ASC has recently recommended that every estab-
lishment and ethical review board develops ways to avoid procedures involving severe suffer-
ing, with the ultimate goal of eliminating severe suffering altogether.[12]
Given that many of the studies are now several years old it might be argued that the sort
of harms reported in these studies would no longer be inflicted on animals, but critically, we
found no indication of a trend towards improvement; thrombolytic studies, of which more
were conducted in the 2000s than in other decades (mode year of publication 2002) and cor-
ticosteroid studies (mode year of publication 2005), continued to inflict severe harms on
animals. All of the studies reviewed here were conducted prior to the publication in 2010
and 2011 of the ARRIVE Guidelines[43] and the Gold Standard Publication Checklist[44]
for reporting animal research. As these guidelines are intended to improve not only report-
ing but also research quality and animal welfare the hope might be that they will ultimately
reduce animal suffering. However, neither of these guidelines require reporting on the use
of restraints and paralytics, the fate of mothers where foetuses or neonates are used, details
of additional related procedures, the severity classification of the research nor humane end-
points (although the ARRIVE guidelines require reporting of welfare-related assessments).
Furthermore, the ARRIVE guidelines do not yet appear to have resulted in improved
reporting standards.[45] Similarly, while more of the journals that publish animal experi-
ments now require author assurance of adherence to ethical standards,[46] compliance with
ethical guidelines does not necessarily lead to actual improvements in animal welfare,[47]
nor does nor the fact that experiments have gained ethical approval.[48, 49] Guidelines have
the potential to improve reporting standards, provide clear data[50] and ultimately improve
animal welfare, but they require enforcement from all concerned, including journals and
reviewers.
Our study suggests that bodies involved in funding, reviewing and authorising animal stud-
ies need to pay greater attention to possibilities for refinement, particularly the use of prede-
fined humane endpoints and the consistent use of anaesthesia and analgesia, including for
neonates and foetuses. Had such refinements been employed in these studies they may well
have reduced animal suffering. There is increasing attention to the refinement component of
the 3Rs[40, 47, 48, 51] as well as its potential impact on research[52] and this is to be wel-
comed. However, given the increasing range of non-animal technologies available[53] the
potential for replacement should also be robustly addressed at the stage that projects are being
considered for approval.
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This was not an ‘audit’ of the prospective HBA process; an HBA was not a legal requirement
for most of these studies since they were either conducted in countries that do not require a
formal HBA, or in Europe prior to 2013. Nevertheless, this is the first time a systematic retro-
spective HBA of a range of pre-clinical animal studies has been conducted and it is perhaps
remarkable that the fitness for purpose and accountability of the prospective HBA has not
been previously investigated in this way. As noted above, public support for animal research is
conditional upon the minimisation of harms to animals and upon benefits to humans and
other animals. This HBA found that that the majority of studies involved severe animal suffer-
ing. Many animals suffered severe harms that were not associated with human benefit. Only
the moderate bisphosphonate studies, less than 7% of the total, appeared to minimise harms to
animals whilst being associated with benefit for humans. Some studies (corticosteroids and
Tirilazad) not only inflicted severe suffering on animals but were associated with increased
human mortality. The regulatory systems in place when these studies were conducted failed to
safeguard animals from severe suffering or to ensure that only beneficial, scientifically rigorous
research was conducted.
At present responsibility for the prospective authorisation of animal studies is spread
amongst research teams, ethical review boards (Animal Welfare and Ethical Review Boards, or
AWERBs in the UK), peer reviewers of funding applications, and licensing bodies (such as the
UK’s Home Office).[54] Consequently, crucial checks relating to scientific rigour, likelihood
of benefit, the availability of non-animal technologies and the assessment and minimisation of
animal harms may be conducted in an inconsistent and disparate manner, with no guarantee
that the bodies involved hold the appropriate expertise. Research quality for example, is—in
the UK at least–mainly the responsibility of peer reviewers who assess funding applications to
determine whether the sample size and experimental design are appropriate.[54] However, the
poor quality of the animal studies reviewed here and elsewhere[35, 37, 39, 55, 56] suggests that
these aspects are not adequately addressed in the peer review process. To ensure that the HBA
is fit for purpose, project applications involving animals need to be rigorously scrutinised to
ensure that only scientifically robust studies that minimise animal harms and have a strong
likelihood of benefit are authorised. This requires both more accurate prospective assessments
and tighter regulatory procedures.
This retrospective HBAs highlights factors that may improve the prospective assessment of
animal studies. Whilst research quality and animal harms are already assessed prospectively, it
is difficult to predict in advance how important or beneficial a research study will be. Our
study found that higher citation scores for animal studies appeared to relate to their clinical
relevance. This raises the possibility of using citation scores to investigate a research team’s
track record, permitting insight into the likely impact of their future studies. Accurate predic-
tion of a study’s future benefits is more challenging, however, and relatively little effort has
gone into improving the accuracy of this aspect of the prospective HBA.[2] The problem is
compounded by a tendency among scientists to be over optimistic about the potential benefits
of their research, particularly when seeking funding.[57, 58] This optimism, together with an
implicit confidence in animal research,[59, 60] is likely to bias assessments towards a predic-
tion of benefit. Yet increasing doubts about the validity of findings derived from animal stud-
ies[35–39, 55, 61–65] and their translation to humans[20, 22, 66–70] suggest that such
confidence may be unwarranted. So how can the likelihood of only authorising beneficial pre-
clinical animal research be increased? First, we found that concordance between animal and
human studies appeared to relate to clinical relevance. If animal and human studies within the
field of interest are ongoing and are being conducted concurrently (as is often the case),
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concordance between the animal and human data in that field can be assessed as part of a pro-
spective HBA to investigate the likelihood of the animal studies having clinical relevance. Sec-
ond, our research found that a greater percentage of studies in concordant interventions had
pharmaceutical company involvement; it is possible that pharmaceutical companies influence
experimental design for the better, or involve greater communication between pre-clinical and
clinical scientists, leading to greater relevance. Further research is needed to explore whether
this is the case and what the implications might be.
In terms of regulation, ethical review boards have been described as the lynchpin of the
HBA[12] and we suggest that the robustness of the HBA might be enhanced by increasing
the level, range and consistency of expertise on such boards so that, in addition to consider-
ing animal welfare and refinements, each board includes an expert in statistics and experi-
mental design to guarantee scientific rigour (and ensure that animals’ lives are not ‘wasted’)
and an expert in non-animal technologies to guarantee that animal use is absolutely neces-
sary. To enhance the likelihood of only beneficial pre-clinical animal studies being autho-
rised, we recommend that funding and licensing bodies make it a requirement for project
applicants, as part of their application, to conduct a systematic review of animal studies
in their field[71, 72] and to relate the systematic review findings to the relevant clinical
research. This would allow reviewers to assess the status and strength of the evidence in the
field, the need for the proposed study (thus avoiding unnecessary replication) and the extent
of concordance with any existing clinical data. We also suggest that funding bodies, licens-
ing bodies, peer reviewers and ethical review boards adopt a precautionary approach when
assessing animal studies so that instead of automatically making an assumption of benefit,
they in fact presume (in line with the evidence noted above) that the research is unlikely to
be beneficial. These measures would place the burden of proof on those submitting propos-
als and encourage them to make a much stronger case for any anticipated benefits. Finally,
the involvement of experts from a greater range of disciplines (e.g. epidemiology, public
health, clinical research) in the reviewing and authorisation of studies would enable wider
questions to be asked, such as ‘Is the aim of this project appropriate?’ and if so, ‘Is animal
research the best way to answer it?’
In terms of research, we recommend that the relevance to humans of pre-clinical animal
research is systematically evaluated,[73] an undertaking that the UK government’s chief scien-
tific advisor also regards as important. In his 2016 lecture to the animal research community,
he asked: ‘To what extent have we as a community, ever subjected our claims about how vital
animal research has been to human health to the same level of scrutiny we’d apply to those
claiming to have discovered a new cure? And I think if not, we must.’[74]
Conclusion
The HBA is a cornerstone of animal research regulation and is considered to be a key ethical
safeguard for animals. This is the first time its accountability has been systematically explored
across a range of pre-clinical animal studies. This HBA found that that the majority of studies
involved severe animal suffering. Many animals suffered severe harms that were not associated
with benefits for humans. Only a small proportion of studies minimised harms to animals
whilst being associated with human benefit. The regulatory systems in place when these studies
were conducted failed to safeguard animals from severe suffering or to ensure that only benefi-
cial, scientifically rigorous research was conducted. Our findings indicate an urgent need to: i.
review regulations, particularly those that permit animals to suffer severe harms; ii. reform the
processes of prospectively assessing pre-clinical animal studies to make them fit for purpose;
and iii. systematically evaluate the relevance to humans of bodies of pre-clinical animal
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research that have already been conducted, to provide a more realistic assessment of its likely
future benefits and increase the accuracy of prospective HBAs.
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